Cerus (CERS) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Cerus Corporation Reports Second Quarter 2015 Results
August 6, 2015 4:01 PM EDTCONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS) today announced financial results for the second quarter ended June 30, 2015.
Recent company highlights include:
Second quarter disposable kit demand increased 32% year over year. Signed INTERCEPT platelet and plasma supply agreements with Unyts and Bonfils Blood Center. Suncoast Blood Bank produced the first INTERCEPT pathogen reduced platelet components distributed in the continental United States. Appointed Richard J. Benjamin, MD, PhD as chief medical officer. Received FDA approval of Phase IV PIPER study... More